New Delhi (ABC Live): India’s pharmaceutical regulation has reached a clear turning point. With the January 2026 amendments to the New Drugs and Clinical Trials (NDCT) Rules, 2019, the Union Government has not only shortened approval pathways but has also deliberately redefined accountability between the regulator and the industry.

At first glance, these changes appear to be routine Ease of Doing Business measures. However, a closer reading shows something deeper. In practice, India is moving away from permission-heavy controls and toward trust-based, post-facto regulation. As a result, while timelines shrink, legal and compliance responsibility expands for sponsors and CROs.

Accordingly, this revised ABC Live Critical Explainer strengthens flow and readability while covering every core aspect—policy intent, legal changes, workflow impact, global comparison, DSLA’s compliance view, verification, and sources.

 Why NDCT Needs Reform Now

For decades, India focused on being the pharmacy of the world. Today, however, that ambition has broadened. India now seeks to become a global centre for R&D, bioequivalence science, and formulation development.

To move in that direction, regulators had to act on three fronts. First, they needed to speed up early-stage research. Second, they had to create predictable timelines for BA/BE studies. Third, they had to align domestic rules with global, risk-based regulatory systems.

Previously, the NDCT framework required routine approvals even when public-health risk remained low. Consequently, research timelines stretched without a matching safety benefit. Therefore, the Government introduced the January 2026 amendments to remove such low-value delays.

At the same time, this logic reinforces ABC Live’s earlier analysis on integrated pharmacology, which explained why faster, science-led regulation is essential for innovation.
👉 Explained | How India Can Benefit from Integrated Pharmacology
https://abclive.in/2025/11/07/explained-how-india-can-benefit-from-integrated-pharmacology/

What Changed Under NDCT 2026

Test Licence Replaced by Prior Intimation (Non-Commercial Manufacture)

Earlier, companies had to obtain a test licence from the Central Drugs Standard Control Organisation (CDSCO) before manufacturing small quantities of drugs for research or analysis.

Now, by contrast, the rules operate differently:

• First, companies no longer need a licence for non-commercial manufacture
• Second, they may begin work after online prior intimation
• Third, regulators still require licences for a limited set of high-risk drugs (cytotoxic, narcotic, psychotropic)

As a result, early drug development progresses around 90 days faster.

Faster Timelines Where Licences Still Apply

Even so, licences have not disappeared entirely. Where they remain necessary:

• CDSCO must decide applications within 45 days, instead of 90 days

Because CDSCO processes 30,000–35,000 applications each year, this change directly reduces regulatory backlog and uncertainty.

BA/BE Studies: From Permission to Intimation

Similarly, for selected low-risk BA/BE studies:

• Sponsors no longer seek prior approval
• Instead, they may begin studies after online notification

Since CDSCO handles 4,000–4,500 BA/BE applications annually, this reform primarily benefits the generic pharmaceutical sector.

Digital-First Compliance via SUGAM and NSWS

At the same time, regulators have moved all workflows online through:

• SUGAM Portal
• National Single Window System (NSWS)

On the one hand, this improves transparency and traceability. On the other hand, it also creates a permanent digital record that regulators can audit at any stage.

Before vs After NDCT | How the Workflow Changed

Non-Commercial Manufacture (Research / Examination)

In effect, the system removes the delay upfront. At the same time, it strengthens scrutiny at a later stage.

Low-Risk BA/BE Studies

Therefore, speed increases. However, responsibility also shifts clearly to the sponsor.

The Core Shift | From Delay Risk to Liability Risk

Earlier, companies mainly worried about waiting for approvals. Now, they focus on defending compliance during inspections.

Put differently:

• Earlier: “Did the regulator approve this?”
• Now: “Can we justify this decision if inspected?”

Thus, while speed improves at the start, legal exposure rises later.

Global Comparison Box | FDA vs EMA/EU vs CDSCO

Overall, India aligns with global regulatory thinking. Nevertheless, enforcement strength will determine whether this model succeeds.

DSLA Section | Legal and Compliance View

Dinesh Singh Law Associates (DSLA) treats the NDCT amendments as a shift in responsibility, rather than deregulation. “NDCT 2026 replaces regulatory delay with regulatory liability.”

DSLA’s Core Compliance Reading

• First, intimation functions as a legal declaration, not a formality

• Second, trust-based systems usually bring more focused audits, not leniency

• Third, sponsors and CROs must clearly divide duties, documentation, and risk

DSLA Advisory Quote: “The NDCT amendments reward strong compliance systems. At the same time, they expose the weak ones. Speed comes first; scrutiny inevitably follows.”

— DSLA Research & Regulatory Advisory

How We Verified This Report

To ensure accuracy and balance, we followed a layered verification process:

First, we relied on primary sources

• PIB release dated 28 January 2026
  👉 https://www.pib.gov.in/PressReleasePage.aspx?PRID=2219422&reg=3&lang=1
• Official material from the Ministry of Health and Family Welfare and CDSCO
• Next, we carried out legal checks

NDCT Rules, 2019 (as amended) Statutory timelines and scope of intimation

Thereafter, we mapped workflows

• Old versus new approval paths
• Portal-based compliance review

In parallel, we benchmarked globally

• FDA and EU CTR design comparison

Finally, DSLA conducted an independent legal review

• Sponsor–CRO liability trends
• Inspection and audit readiness

Final Assessment | ABC Live View

What NDCT 2026 Gets Right

• Cuts avoidable delays
• Speeds up R&D and BA/BE work
• Reduces regulatory congestion
• Signals global maturity

What Still Needs Attention

• Strong post-market surveillance
• Consistent inspections
• Clear penalties for misuse
• Sustained global trust in Indian data

Bottom Line

The NDCT amendments are timely and well-designed. They reflect confidence in India’s pharmaceutical ecosystem and follow global regulatory trends. Yet, they do not deregulate the system. Instead, they redistribute liability.

For well-run sponsors and CROs, NDCT 2026 creates a clear advantage. Conversely, for weak systems, it presents a serious test.

**India has chosen speed—and, with it, trust.
Ultimately, the coming years will show whether that trust delivers results.